Iorfino, Frank
Varidel, Mathew
Capon, William
Richards, Matthew
Crouse, Jacob J.
LaMonica, Haley M.
Park, Shin Ho
Piper, Sarah
Song, Yun Ju Christine
Gorban, Carla
Scott, Elizabeth M.
Hickie, Ian B.
Funding for this research was provided by:
Bill and Patricia Ritchie Foundation Fellowship (NA)
Australian Government Research Training Program (RTP) Scholarship (NA)
NHMRC Emerging Leadership Fellowship (GNT2008197)
NHMRC Australia Fellowship (511921)
Article History
Received: 6 July 2023
Accepted: 8 June 2024
First Online: 8 July 2024
Competing interests
: A/Prof Elizabeth Scott is Principal Research Fellow at the Brain and Mind Centre, The University of Sydney. She is Discipline Leader of Adult Mental Health, School of Medicine, University of Notre Dame, and a Consultant Psychiatrist. She was the Medical Director, Young Adult Mental Health Unit, St Vincent’s Hospital Darlinghurst until January 2021. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier, Janssen and Eli-Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. She was the National Coordinator of an antidepressant trial sponsored by Servier. Professor Ian Hickie is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017-20; a three-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies.All other authors declare no competing interests.